Major US-based private equity firm Blackstone Group, Inc. has emerged as the most likely buyer of Takeda Pharmaceutical Company Limited.’s consumer health business in Japan, as multiple media reports in the country say a deal valued at up to $2.8bn could be signed by the end of the month.
Blackstone Emerges As Likely Buyer Of Takeda OTC Business
Up To $2.8bn Deal Soon?
Private equity group Blackstone is reportedly near a deal to acquire Takeda's consumer health business in Japan for up to $2.8bn as the Japanese pharma firm continues to shed non-core assets.
